Process for preparing distamycin derivatives

Details Process for preparing distamycin derivatives Process for preparing distamycin derivatives

2005-06-14

2005-06-14

Campell, Bruce R. (Department: 1654)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C530S332000, C530S300000, C530S333000, C514S018700, C514S019300, C514S020800, C548S312400, C548S312700, C548S313100, C548S314700, C548S364100, C548S365100, C548S518000

Reexamination Certificate

active

06906199

ABSTRACT:
It is described a process for preparing, in high yields and purity and without the need of carrying out several steps and/or isolating many intermediates which could lead to undesired by-products, a distamycin derivative of formulawherein R is a bromine or chlorine atom; or a pharmaceutically acceptable salt thereof. The compounds of formula (I) are useful in therapy as antitumor agents.

REFERENCES:
patent: 5646177 (1997-07-01), Koch et al.
patent: 5880097 (1999-03-01), Lyttle et al.
patent: 0 246 868 (1987-11-01), None
patent: 0 265 719 (1988-05-01), None
patent: 0 388 948 (1990-09-01), None
patent: 0 420 121 (1991-04-01), None
patent: 90/11277 (1990-10-01), None
patent: 96/05196 (1996-02-01), None
patent: 97/43258 (1997-11-01), None
patent: 98/04524 (1998-02-01), None
patent: 98/21202 (1998-05-01), None
patent: 99/34796 (1999-07-01), None
patent: 99/50265 (1999-10-01), None
patent: 99/50266 (1999-10-01), None
patent: 00/06541 (2000-02-01), None
patent: 00/06542 (2000-02-01), None
Cozzi P et al.: “Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, No. 11, Jun. 2000.
XP-001039783: “Elevation of Placental Glutathione S-Tranferase Form (GST-π) in Tumor Tissues and the Levels in Sera of Patients with Cancer,” Tsuchida et al., Cancer Research 49, pp. 5225-5229, Sep. 15, 1989.
XP-001039581: “Synthesis and Antitumor Activity of New Benzoheterocyclic Derivatives of Distamycin A,” Baraldi et al., J. Med. Chem. 2000, 43, pp. 2675-2684, Jun. 27, 2000.
XP-001039865: #5240 In Vivo Induction of Apotosis with PNU-166196 In Human Ovarian Carcinoma Xenografts, Giusti et al., Pharmacia & Upjohn, Nerviano (Mi), Italy, p. 825, Mar. 2000.
XP-001039805: “A new class of cytotoxic DNA minor groove binders: α-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers,” Paolo Cozzi, II Farmaco 56 (2001) 57-65.
XP-001039737: “Non-chemotherapeutic agents that potentiate chemotherapy efficacy,” David J. Stewart and William K. Evans, Cancer Treatment Reviews (1989) 16: 1-40.
XP-002104215: “The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule,” Sola et al., Cancer Chemother Pharmacol (1999) 43: 241-246.
XP-002110339: “Gemcitabine: Future Prospects of Single-Agent and Combination Studies,” Van Moorsel et al., Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands, pp. 127-134, 1997.
“Cytotoxic Halogenoacrylic Derivatives of Distamycin A,” P Cozzi et al., Bioorganic & Medicinal Chemistry Letters 10(2000) 1269-1272.
XP-002104217: “Distamycin-A Derivatives Potentiate Tumor-Necrosis-Factor Activity Via the Modulation of Tyrosine Prosphorylation,” Int. J. Cancer: 72, 810-814 (1997).
XP-000671766: “Structure-Activity Relationship of Novel Distamycin A Derivatives: Synthesis and Antitumor Activity,” D'Alessio et al., Bioorganic & Medical Chemistry Letters, vol. 4, No. 12, pp. 1467-1472, 1994.
XP-002191966: “Fluorosulfonic Acid,” p. 740, Paragraph 4206 (2001).
XP-001039733: “Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents,” British Journal of Cancer (1999) 80 (3/4), 338-343.
XP-001039861: #2708 “Antitumor Activity of PNU-166196, A Novel DNA Minor Groove Binder Selected for Clinical Development,” Geroni et al., pp. 425-426, Mar. 2000.
Original Paper, “Combination of the New Minor Groove Alkylator Tallimustine and Melphalan,” Tagliabue et al., European Journal of Cancer, vol. 33, No. 2, pp. 284-287, 1997.
XP-002181404: “Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity,” Boger et al., J. Am. Chem. Soc. 2000, 122, 6382-6394.
“Synthesis and Antitumor Activity of Novel Distamycin Derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 11 , pp. 1241-1246, 1996.
“Combination Therapy with Gemcitabine in Non-small Cell Lung Cancer,” Mosconi et al., European Journal of Cancer, vol. 33, Suppl. 1, pp. 514-517, 1997.
XP-001039871: “PNU-166196: A Novel Antitumor Agent Whose Cytotoxicity is Enhanced in Tumor Cells with High Levels of Glutathione,” Geroni et al., pp. 41-42, Jul. 2000.

Affiliated with

Also associated with

Rating

Process for preparing distamycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for preparing distamycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing distamycin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3464047